Simon Grøntved, Kathrine Hald, Christina Mohr-Jensen, Søren Paaske Johnsen, Jan Mainz, Jan Brink Valentin
{"title":"丹麦注意缺陷/多动障碍的患病率和发病率。一项基于国家登记的开放队列研究。","authors":"Simon Grøntved, Kathrine Hald, Christina Mohr-Jensen, Søren Paaske Johnsen, Jan Mainz, Jan Brink Valentin","doi":"10.1111/acps.13804","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Rises in prevalence and incidence of the neurodevelopmental disorder Attention-deficit/Hyperactivity Disorder (ADHD) have been reported globally and estimated in Denmark previously. Nevertheless, differences in methodology hinder an assessment of the temporal evolution of ADHD based on published literature. The aim of this study was to consistently calculate the yearly prevalence and incidence proportions of ADHD and the use of ADHD medication in Denmark from 2000 to 2022.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted an open cohort study using register data covering the entire Danish population. We defined ADHD as either having a hospital diagnosis of ADHD (ICD-10: F90.0, F90.1, F90.8, or F98.8), or having redeemed a prescription for ADHD medication.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of the included 7,748,837 persons, 2.52% had ADHD, of whom 58.33% were males. The prevalence of ADHD has increased from 0.10% in 2000 to 3.03% in 2022. Specifically for the 18–27-year-olds, the prevalence was 8.16% for males and 6.12% for females in the year 2022. For the incidence, the same age group peaked within the females in 2022 at 1.10%, whereas the male incidence was consistently highest in the 6–18-year-olds, peaking in 2022 at 0.94%. Total use of ADHD medication in the population also increased. Methylphenidate was used by 97.58% of the ADHD medicated patients in 2000 and 70.60% in 2022. Lisdexamphetamine was the second most common in 2022, where 24.03% redeemed a prescription.</p>\n </section>\n \n <section>\n \n <h3> Limitations</h3>\n \n <p>Incidence and prevalence were calculated specifically for the Danish population and may not be directly generalizable to other countries.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The prevalence of ADHD has consistently increased throughout the past two decades. The main contribution to this increase is the ADHD incidence in females, especially young females in the most recent years 2020–2022. Methylphenidate was consistently the most common ADHD drug prescribed, though lisdexamphetamine use has increased in recent years.</p>\n </section>\n </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"152 1","pages":"27-38"},"PeriodicalIF":5.0000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.13804","citationCount":"0","resultStr":"{\"title\":\"Prevalence and Incidence of Attention Deficit/Hyperactivity Disorder in Denmark. A National Register-Based Open Cohort Study\",\"authors\":\"Simon Grøntved, Kathrine Hald, Christina Mohr-Jensen, Søren Paaske Johnsen, Jan Mainz, Jan Brink Valentin\",\"doi\":\"10.1111/acps.13804\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Rises in prevalence and incidence of the neurodevelopmental disorder Attention-deficit/Hyperactivity Disorder (ADHD) have been reported globally and estimated in Denmark previously. Nevertheless, differences in methodology hinder an assessment of the temporal evolution of ADHD based on published literature. The aim of this study was to consistently calculate the yearly prevalence and incidence proportions of ADHD and the use of ADHD medication in Denmark from 2000 to 2022.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We conducted an open cohort study using register data covering the entire Danish population. We defined ADHD as either having a hospital diagnosis of ADHD (ICD-10: F90.0, F90.1, F90.8, or F98.8), or having redeemed a prescription for ADHD medication.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Of the included 7,748,837 persons, 2.52% had ADHD, of whom 58.33% were males. The prevalence of ADHD has increased from 0.10% in 2000 to 3.03% in 2022. Specifically for the 18–27-year-olds, the prevalence was 8.16% for males and 6.12% for females in the year 2022. For the incidence, the same age group peaked within the females in 2022 at 1.10%, whereas the male incidence was consistently highest in the 6–18-year-olds, peaking in 2022 at 0.94%. Total use of ADHD medication in the population also increased. Methylphenidate was used by 97.58% of the ADHD medicated patients in 2000 and 70.60% in 2022. Lisdexamphetamine was the second most common in 2022, where 24.03% redeemed a prescription.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Limitations</h3>\\n \\n <p>Incidence and prevalence were calculated specifically for the Danish population and may not be directly generalizable to other countries.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>The prevalence of ADHD has consistently increased throughout the past two decades. The main contribution to this increase is the ADHD incidence in females, especially young females in the most recent years 2020–2022. Methylphenidate was consistently the most common ADHD drug prescribed, though lisdexamphetamine use has increased in recent years.</p>\\n </section>\\n </div>\",\"PeriodicalId\":108,\"journal\":{\"name\":\"Acta Psychiatrica Scandinavica\",\"volume\":\"152 1\",\"pages\":\"27-38\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2025-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.13804\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Psychiatrica Scandinavica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/acps.13804\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Psychiatrica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/acps.13804","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Prevalence and Incidence of Attention Deficit/Hyperactivity Disorder in Denmark. A National Register-Based Open Cohort Study
Introduction
Rises in prevalence and incidence of the neurodevelopmental disorder Attention-deficit/Hyperactivity Disorder (ADHD) have been reported globally and estimated in Denmark previously. Nevertheless, differences in methodology hinder an assessment of the temporal evolution of ADHD based on published literature. The aim of this study was to consistently calculate the yearly prevalence and incidence proportions of ADHD and the use of ADHD medication in Denmark from 2000 to 2022.
Methods
We conducted an open cohort study using register data covering the entire Danish population. We defined ADHD as either having a hospital diagnosis of ADHD (ICD-10: F90.0, F90.1, F90.8, or F98.8), or having redeemed a prescription for ADHD medication.
Results
Of the included 7,748,837 persons, 2.52% had ADHD, of whom 58.33% were males. The prevalence of ADHD has increased from 0.10% in 2000 to 3.03% in 2022. Specifically for the 18–27-year-olds, the prevalence was 8.16% for males and 6.12% for females in the year 2022. For the incidence, the same age group peaked within the females in 2022 at 1.10%, whereas the male incidence was consistently highest in the 6–18-year-olds, peaking in 2022 at 0.94%. Total use of ADHD medication in the population also increased. Methylphenidate was used by 97.58% of the ADHD medicated patients in 2000 and 70.60% in 2022. Lisdexamphetamine was the second most common in 2022, where 24.03% redeemed a prescription.
Limitations
Incidence and prevalence were calculated specifically for the Danish population and may not be directly generalizable to other countries.
Conclusions
The prevalence of ADHD has consistently increased throughout the past two decades. The main contribution to this increase is the ADHD incidence in females, especially young females in the most recent years 2020–2022. Methylphenidate was consistently the most common ADHD drug prescribed, though lisdexamphetamine use has increased in recent years.
期刊介绍：
Acta Psychiatrica Scandinavica acts as an international forum for the dissemination of information advancing the science and practice of psychiatry. In particular we focus on communicating frontline research to clinical psychiatrists and psychiatric researchers.
Acta Psychiatrica Scandinavica has traditionally been and remains a journal focusing predominantly on clinical psychiatry, but translational psychiatry is a topic of growing importance to our readers. Therefore, the journal welcomes submission of manuscripts based on both clinical- and more translational (e.g. preclinical and epidemiological) research. When preparing manuscripts based on translational studies for submission to Acta Psychiatrica Scandinavica, the authors should place emphasis on the clinical significance of the research question and the findings. Manuscripts based solely on preclinical research (e.g. animal models) are normally not considered for publication in the Journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
